The Centers for Medicare & Medicaid Services (CMS) will separately pay for specialized diagnostic radiopharmaceuticals for Medicare patients in hospital outpatient settings starting in 2025. This decision eliminates the transitional pass-through payment period and ensures consistent reimbursement. Payments will be based on Mean Unit Cost (MUC) derived from hospital claims data, applying to products costing over US$630 per day. This impacts Telix's Illuccix from July 1, 2025, and its pipeline products TLX007-CDx, TLX250-CDx, and TLX101-CDx if approved and reimbursed. Telix will be the only company with two PSMA-PET imaging agents if TLX007-CDx is approved, expanding patient reach.